Alan Watt

Company: NodThera Ltd.
Job title: President & Chief Scientific Officer
Seminars:
Preclinical & Clinical Evaluation of the Brain Penetrant NLRP3 Inhibitor, NT-0796 in Obesity & Cardiometabolic Disease 9:30 am
Highlighting favorable shifts in cardiovascular biomarkers linked to reduced inflammation-driven cardiometabolic risk Underscoring the role of hypothalamic inflammation as a therapeutic target in obesity Showcasing oral NLRP3 inhibition as a strategy to improve key metabolic parameters in individuals with obesityRead more
day: Conference Day One AM